SCOTTSDALE, Ariz., March 1, 2010 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced the launch of its new program, the “Dysport Challenge.” Approved by the U.S. Food and Drug Administration (FDA) in April 2009, Dysport (abobotulinumtoxinA) is a prescription injection used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.
